Natco Pharma launches generic blood cancer drug in India
Latest News »
- RSS arm demands clear policy on child malnutrition problem
- Reliance Industries eyes $300 million boost from switch to ethane
- Govt clarifies on GST rates for ad agencies offering print media space
- Chinese solar module firms reneging on India contracts
- Britannia to invest Rs100 crore to boost premium biscuit market share
New Delhi: Natco Pharma on Wednesday said it has launched a generic version of pomalidomide capsules, used in treatment of a type of blood cancer, in India.
“Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy,” Natco said in a Bombay Stock Exchange (BSE) filing.
Myeloma is a type of blood cancer. Natco has launched pomalidomide capsules in strengths of 1 mg, 2 mg and 4 mg in India. Pomalidomide is sold by Celgene Inc., in the US, under the brand name POMALYST.
Natco Pharma said it will market generic pomalidomide capsules under its brand name POMALID in India. Natco has priced its generic medicine of POMALID 1 mg, 2 mg, and 4 mg capsules at an MRP Rs5,000, Rs10,000 and Rs20,000 respectively, for a monthly pack of 21 capsules, the company said.
“We believe, this is approximately 98% discount of price from what it is sold at in the US to patients, as per secondary market data researched,” the company added. Shares of Natco Pharma were trading 1.52% up at Rs909 on BSE.